Haemonetics Expands Its Innovative Medical Offerings
Haemonetics Corporation (NYSE: HAE), a trailblazer in the medical technology landscape, has taken a significant step by acquiring Vivasure Medical Limited, a company renowned for its pioneering efforts in advanced vessel closure technology. This acquisition marks a pivotal moment for Haemonetics, bolstering its commitment to improving patient outcomes through innovative solutions.
Introducing Vivasure's Pioneering Technology
At the heart of Vivasure's offerings is the PerQseal Elite system, which employs a unique bioabsorbable patch designed for the closure of large-bore arteriotomies and venotomies from the inside. This technology, celebrated for its sutureless and absorbable nature, targets enhancing efficiency in structural heart and endovascular procedures. The adoption of innovative procedures has been expedited by recent milestones, including a Premarket Approval submission to the U.S. FDA and achieving CE Mark approval in Europe for both arterial and venous uses.
Clinical Achievements and Performance
Results from the ELITE arterial study, which involved a detailed, prospective, single-arm, multi-center research approach, underline the efficacy of the PerQseal Elite system. The study revealed an unprecedented ease of use with no pre-close requirements and a remarkable zero percent major complications rate at a thirty-day follow-up, emphasizing the system's reliability.
Financial Aspects of the Acquisition
The agreement for the acquisition stands at €100 million upfront, with an opportunity for an additional €85 million contingent on sales performance and achievement of set milestones. This strategic acquisition is financed through Haemonetics' current cash reserves, reinforcing its financial strength and commitment to investing in innovative healthcare solutions.
Leadership Insights
Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, expressed enthusiasm about the acquisition, stating, "This move expands our comprehensive range of closure devices, integrating clinically differentiated technology that positions us prominently in the burgeoning large-bore closure market." The move signifies a strategic advantage as Haemonetics aims to enhance its operational synergies to deliver exceptional value to clinicians and healthcare facilities.
Vivasure's Vision Aligns with Haemonetics' Goals
Andrew Glass, the CEO of Vivasure Medical Limited, remarked on the acquisition, highlighting the added strength that Haemonetics brings to his company’s vision. He stated, "Joining Haemonetics equips us with the global scale and resources necessary to expedite the delivery of PerQseal Elite, making its clinical benefits accessible to a broader audience of healthcare professionals and patients around the world." This shared vision between both companies promises to enhance the standard of care within the healthcare sector.
About Haemonetics Corporation
Haemonetics Corporation is dedicated to enhancing the quality and efficiency of healthcare. The company's diverse portfolio addresses critical medical needs, ranging from hospital technologies to plasma collection solutions and blood component collection. With ongoing innovations, Haemonetics strives to set new standards in improving patient experiences and outcomes.
About Vivasure Medical Limited
Vivasure Medical Limited focuses on developing cutting-edge polymer implants and delivery mechanisms tailored for minimally invasive vessel closure. Based in Galway, Ireland, Vivasure benefits from a fully integrated research and development facility that meets stringent standards, positioning it as a leader in cardiovascular and interventional medical solutions.
Frequently Asked Questions
What is the main goal of Haemonetics' acquisition of Vivasure?
The primary goal is to enhance Haemonetics' offerings in closure devices, particularly in the large-bore closure market, while leveraging Vivasure's innovative technologies.
What technology is featured in Vivasure's PerQseal Elite system?
The PerQseal Elite system utilizes a proprietary bioabsorbable patch to provide a sutureless and fully absorbable solution for vessel closure in various medical procedures.
How much was the acquisition of Vivasure Medical Limited?
Haemonetics agreed to an initial payment of €100 million, with the potential for an additional €85 million based on performance-related milestones.
What are some clinical outcomes of the PerQseal Elite system?
The system demonstrated zero major complications in a thirty-day follow-up and required no pre-close, highlighting its effectiveness in clinical settings.
What does the acquisition signify for the future of Haemonetics?
This acquisition positions Haemonetics for increased market leadership in advanced closure technology, enhancing their impact on patient care and expanding their product portfolio.
